AC Immune (ACIU) vs SAB Biotherapeutics, Inc. (SABS)
- AC Immune ACIU 2.39 −2.45%
- SAB Biotherapeutics, Inc. SABS 2.53 −2.32%
AC Immune and SAB Biotherapeutics, Inc. are both Biotechnology companies. AC Immune and SAB Biotherapeutics, Inc. are of similar size ($249.4M and $235.7M). SAB Biotherapeutics, Inc. grew revenue faster over the last twelve months: −60.3% against −85.6%. SAB Biotherapeutics, Inc. has the higher net margin (0.00% vs −1,783.7%) and the lower return on invested capital (−39.0% vs 0.00%). Across the 16 metrics below, AC Immune leads on 8 and SAB Biotherapeutics, Inc. on 8.
Valuation
Profitability
| Metric | ACIU | SABS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (1,745.75%) | 0.00% | 0.00% |
| Net margin | (1,783.66%) | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | 0.00% | (19.21%) | (56.36%) |
| Return on assets | 0.00% | (16.24%) | (48.04%) |
| Return on invested capital | 0.00% | (38.97%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack